Is ZNTL or INCR more profitable?

InterCure's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% InterCure N/A N/A N/A

Do analysts rate INCR or CRDL?

Cardiol Therapeutics has a consensus target price of $10.00, indicating a potential upside of 433.33%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is INCR or CRDL more profitable?

InterCure's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Cardiol Therapeutics N/A -180.44% -140.28%

Do analysts prefer SIGA or INCR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate INCR or DERM?

Journey Medical has a consensus target price of $14.00, indicating a potential upside of 91.52%. Given Journey Medical's stronger consensus rating and higher probable upside, analysts clearly believe Journey Medical is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Journey Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings and valuation, INCR or DERM?

InterCure has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InterCure $78.47M 0.74 -$10.37M $0.15 35.30 Journey Medical $61.86M 3.33 -$11.43M -$0.22 N/A

Do analysts rate INCR or ANTX?

Anthem has a consensus price target of $9.00, indicating a potential upside of 78.22%. Given Anthem's stronger consensus rating and higher possible upside, analysts plainly believe Anthem is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anthem 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable valuation and earnings, INCR or ANTX?

InterCure has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InterCure $78.47M 0.74 -$10.37M $0.15 35.30 Anthem N/A N/A -$35.17M -$1.07 N/A

Is INCR or ANTX more profitable?

InterCure's return on equity of 0.00% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Anthem N/A -53.52% -48.63%

InterCure (INCR) Competitors

$5.30 -0.02 (-0.28%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$5.32 +0.03 (+0.55%)

As of 09/18/2026 07:30 PM Eastern

Compare

INCR vs. ZNTL, CRDL, SIGA, DERM, and ANTX

Should you buy InterCure stock or one of its competitors? InterCure's main competitors and comparable companies include Zentalis Pharmaceuticals (ZNTL), Cardiol Therapeutics (CRDL), Siga Technologies (SIGA), Journey Medical (DERM), and Anthem (ANTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does InterCure compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Zentalis Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, InterCure has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 0 mentions for InterCure. Zentalis Pharmaceuticals' average media sentiment score of 0.17 beat InterCure's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Neutral
InterCure	Neutral

8.3% of InterCure shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of InterCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zentalis Pharmaceuticals currently has a consensus target price of $6.75, suggesting a potential upside of 117.04%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InterCure has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	3.31	-$137.06M	-$1.95	N/A
InterCure	$78.47M	0.74	-$10.37M	$0.15	35.30

InterCure's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
InterCure	N/A	N/A	N/A

Summary

Zentalis Pharmaceuticals beats InterCure on 8 of the 15 factors compared between the two stocks.

How does InterCure compare to Cardiol Therapeutics?

InterCure (NASDAQ:INCR) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

InterCure's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Cardiol Therapeutics has a consensus target price of $10.00, indicating a potential upside of 433.33%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

8.3% of InterCure shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

InterCure has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.74	-$10.37M	$0.15	35.30
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

In the previous week, Cardiol Therapeutics had 4 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 0 mentions for InterCure. Cardiol Therapeutics' average media sentiment score of 0.44 beat InterCure's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Cardiol Therapeutics	Neutral

InterCure has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Summary

InterCure and Cardiol Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does InterCure compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 0.2% of InterCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

InterCure has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. InterCure's return on equity of 0.00% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
InterCure	N/A	N/A	N/A

In the previous week, Siga Technologies' average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
Siga Technologies	Neutral
InterCure	Neutral

Siga Technologies has higher revenue and earnings than InterCure. Siga Technologies is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.39	$23.28M	-$0.05	N/A
InterCure	$78.47M	0.74	-$10.37M	$0.15	35.30

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Siga Technologies has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, InterCure has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

Summary

InterCure beats Siga Technologies on 6 of the 11 factors compared between the two stocks.

How does InterCure compare to Journey Medical?

InterCure (NASDAQ:INCR) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

InterCure has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.74	-$10.37M	$0.15	35.30
Journey Medical	$61.86M	3.33	-$11.43M	-$0.22	N/A

InterCure has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

8.3% of InterCure shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

InterCure has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. InterCure's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Journey Medical	-8.95%	-20.23%	-6.60%

Journey Medical has a consensus target price of $14.00, indicating a potential upside of 91.52%. Given Journey Medical's stronger consensus rating and higher probable upside, analysts clearly believe Journey Medical is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Journey Medical had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for Journey Medical and 0 mentions for InterCure. Journey Medical's average media sentiment score of 1.40 beat InterCure's score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Journey Medical	Positive

Summary

InterCure beats Journey Medical on 9 of the 16 factors compared between the two stocks.

How does InterCure compare to Anthem?

InterCure (NASDAQ:INCR) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

InterCure's return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Anthem	N/A	-53.52%	-48.63%

8.3% of InterCure shares are held by institutional investors. Comparatively, 90.5% of Anthem shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 22.6% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Anthem had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for Anthem and 0 mentions for InterCure. InterCure's average media sentiment score of 0.00 equaled Anthem'saverage media sentiment score.

Company	Overall Sentiment
InterCure	Neutral
Anthem	Neutral

InterCure has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Anthem has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market.

Anthem has a consensus price target of $9.00, indicating a potential upside of 78.22%. Given Anthem's stronger consensus rating and higher possible upside, analysts plainly believe Anthem is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

InterCure has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.74	-$10.37M	$0.15	35.30
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

Summary

InterCure beats Anthem on 7 of the 13 factors compared between the two stocks.

Get InterCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCR vs. The Competition

Export

Metric	InterCure	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$58.07M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	35.30	797.25	275.49	25.40
Price / Sales	0.74	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	0.50	10.53	10.46	6.33
Net Income	-$10.37M	$2.82B	$3.49B	$358.33M
7 Day Performance	2.62%	1.69%	0.59%	1.12%
1 Month Performance	21.86%	0.24%	-1.74%	-2.39%
1 Year Performance	-27.47%	3.95%	18.13%	5.35%

InterCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCR InterCure	1.1767 of 5 stars	$5.30 -0.3%	N/A	-27.5%	$58.07M	$78.47M	35.30	285
ZNTL Zentalis Pharmaceuticals	3.5046 of 5 stars	$3.10 -1.0%	$6.75 +117.7%	+104.6%	$224.33M	$67.43M	N/A	106	Analyst Forecast
CRDL Cardiol Therapeutics	2.6487 of 5 stars	$1.90 +2.7%	$10.00 +426.3%	+67.4%	$214.93M	N/A	N/A	18	News Coverage
SIGA Siga Technologies	0.2892 of 5 stars	$3.10 +4.0%	N/A	-64.2%	$214.11M	$94.57M	N/A	49
DERM Journey Medical	1.7924 of 5 stars	$7.29 -1.0%	$14.00 +92.0%	+0.1%	$207.73M	$61.86M	N/A	58

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCR) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InterCure (INCR) Competitors

INCR vs. ZNTL, CRDL, SIGA, DERM, and ANTX

How does InterCure compare to Zentalis Pharmaceuticals?

Summary

How does InterCure compare to Cardiol Therapeutics?

Summary

How does InterCure compare to Siga Technologies?

Summary

How does InterCure compare to Journey Medical?

Summary

How does InterCure compare to Anthem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InterCure (INCR) Competitors

INCR vs. ZNTL, CRDL, SIGA, DERM, and ANTX

How does InterCure compare to Zentalis Pharmaceuticals?

Which has more volatility and risk, ZNTL or INCR?

Does the media favor ZNTL or INCR?

Do insiders and institutionals have more ownership in ZNTL or INCR?

Do analysts recommend ZNTL or INCR?

Which has better earnings and valuation, ZNTL or INCR?

Is ZNTL or INCR more profitable?

Summary

How does InterCure compare to Cardiol Therapeutics?

Is INCR or CRDL more profitable?

Do analysts rate INCR or CRDL?

Do insiders & institutionals believe in INCR or CRDL?

Which has stronger earnings & valuation, INCR or CRDL?

Does the media refer more to INCR or CRDL?

Which has more volatility and risk, INCR or CRDL?

Summary

How does InterCure compare to Siga Technologies?

Do institutionals and insiders hold more shares of SIGA or INCR?

Is SIGA or INCR more profitable?

Does the media favor SIGA or INCR?

Which has stronger earnings & valuation, SIGA or INCR?

Do analysts prefer SIGA or INCR?

Which has more risk and volatility, SIGA or INCR?

Summary

How does InterCure compare to Journey Medical?

Which has higher earnings and valuation, INCR or DERM?

Which has more risk and volatility, INCR or DERM?

Do institutionals & insiders have more ownership in INCR or DERM?

Is INCR or DERM more profitable?

Do analysts rate INCR or DERM?

Does the media refer more to INCR or DERM?

Summary

How does InterCure compare to Anthem?

Is INCR or ANTX more profitable?

Do institutionals and insiders have more ownership in INCR or ANTX?

Does the media refer more to INCR or ANTX?

Which has more volatility and risk, INCR or ANTX?

Do analysts rate INCR or ANTX?

Which has preferable valuation and earnings, INCR or ANTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools